Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2019-12-01
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
or
-TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESP group
ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
ESP Block
ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
TAP Block
TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
TAP Block
TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESP Block
ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
TAP Block
TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA status I or II
* scheduled for laparoscopic cholecystectomy
Exclusion Criteria
* unplanned ICU admission
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mongi Slim Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mhamed Sami Mebazaa
professor, head of the anesthesia and ICU departement
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mhamed Sami Mebazaa, Professor
Role: PRINCIPAL_INVESTIGATOR
Mongi Slim Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mongi Slim Hospital
Tunis, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESP in cholecystectomy
Identifier Type: -
Identifier Source: org_study_id